PR Newswire
RADNOR, Pa., April 30, 2020
RADNOR, Pa., April 30, 2020 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) ("Safeguard" or the "Company") today announced financial results for the three months ended March 31, 2020.
Dr. Rosenthal said, "We hold a valuable portfolio of ownership interests and are committed to identifying and executing a range of actions to capitalize on exit opportunities and maximize shareholder value. Earlier this month we announced the addition of Eric Salzman in a newly created role of Chief Restructuring Officer. Eric will be responsible for our value maximization strategy and his prior experience and familiarity with the portfolio make him an excellent choice, especially in light of the current situation. I am excited to partner with Eric to pursue this opportunity."
"Since joining the Safeguard team a month ago, I have been working with our team to respond to COVID-19 related needs of our portfolio companies, meeting the CEOs of our portfolio companies, meeting our shareholders, reviewing the fair market value and exit values of our positions and exploring a range of options to more actively seek exits of our interests," said Mr. Salzman. "Based on my experience, I believe I can effectively contribute to the execution of our strategy to drive results for all stakeholders, notwithstanding the volatile macro environment."
"The more challenging economic environment and less active mergers and acquisition market means that we may have greater need for follow-on fundings to protect our positions and capitalize on opportunities that may have accelerated. As a result, Safeguard's full year 2020 estimate of its liquidity needs increased during the first quarter." said Mark A. Herndon, Safeguard's Senior Vice President and Chief Financial Officer. Our higher expectations for follow-on funding requirements result in a full year 2020 forecast range of between $8 and $12 million, which also includes some acceleration from deployments previously planned for 2021. Corporate expenses for the year ended December 31, 2020 are expected to continue to decline throughout the year. Our new range is forecasted to be $5.6 to $6.0 million as compared to $7.1 million for the year ended December 31, 2019.
During the first quarter of 2020, Safeguard's portfolio companies have been impacted by COVID-19 in a variety of operational ways. Our companies have also been impacted by a greater difficulty securing access to debt or equity capital. We are working with the management teams of the entities in which the Company holds such ownership interests to take actions to respond to the rapidly changing environment, including implementing cost reduction efforts, securing additional capital or other actions, which could mitigate some of the expected impacts. Safeguard management will continue to work with each management team to respond to the rapidly changing environment.
OWNERSHIP INTERESTS AT MARCH 31, 2020
Companies | Category | Acquisition | Primary | Carrying | | Cost | ||
| | | | | | | ||
Initial Revenue Stage: Up to $1 million in revenue | | |||||||
None | | | | | | | ||
Expansion Stage: $1 million to $5 million in revenue | ||||||||
Moxe Health Corporation | Healthcare | 2016 | 29.9% | $ 5.2 | | $ 7.5 | ||
Traction Stage: $5 million to $10 million in revenue | | |||||||
meQuilibrium | Healthcare | 2015 | 32.7% | 4.3 | | 14.0 | ||
Trice Medical, Inc. | Healthcare | 2014 | 16.6% | 1.8 | | 10.4 | ||
Zipnosis, Inc. | Healthcare | 2015 | 37.7% | 2.9 | | 10.0 | ||
QuanticMind, Inc. | Digital Media | 2015 | 24.2% | 2.3 | | 13.7 | ||
WebLinc, Inc. | Digital Media | 2014 | 38.5% | 2.2 | | 16.2 | ||
Lumesis, Inc. | Financial Services | 2012 | 43.5% | 0.5 | | 5.6 | ||
High Traction Stage: $10 million to $15 million in revenue | | |||||||
InfoBionic, Inc. + | Healthcare | 2014 | 25.2% | - | | 22.0 | ||
Clutch Holdings, Inc. | Digital Media | 2013 | 41.2% | 5.3 | | 16.6 | ||
Sonobi, Inc. + | Digital Media | 2015 | 21.6% | 8.4 | | 13.4 | ||
Greater than $15 million in revenue | | |||||||
Aktana, Inc. | Healthcare | 2016 | 17.5% | 2.5 | | 11.7 | ||
Prognos Health, Inc. + | Healthcare | 2011 | 28.7% | 4.9 | | 12.6 | ||
Syapse, Inc. | Healthcare | 2014 | 20.0% | 2.2 | | 21.2 Werbung Mehr Nachrichten zur Safeguard Scientifics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. |